The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Trial Profile

The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Apr 2018

At a glance

  • Drugs Patiromer (Primary)
  • Indications Hyperkalaemia
  • Focus Therapeutic Use
  • Acronyms TOURMALINE
  • Sponsors Relypsa
  • Most Recent Events

    • 11 Apr 2018 According to the Relypsa media release, findings from pooled analysis from this and other two trials (OPAL-HK and AMETHYST-DN) will be presented in a poster session at the National Kidney Foundation's (NKF) 2018 Spring Clinical Meetings (SCM18).
    • 11 Apr 2018 Results from pooled analysis of this and other two trials (OPAL-HK and AMETHYST-DN) presented in the Relypsa media release.
    • 15 Nov 2017 Results of post-hoc analysis assessing patiromer efficacy in hyperkalemic patients with or without RAASi, presented at the 90th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top